Investors & Media

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks Data further strengthen eplontersen’s differentiated profile, positioning it to be an important potential treatment for patients with ATTRv-PN

Read more
You are now leaving to visit